EA200101272A1 - Антагонисты альфа-v интегриновых рецепторов - Google Patents

Антагонисты альфа-v интегриновых рецепторов

Info

Publication number
EA200101272A1
EA200101272A1 EA200101272A EA200101272A EA200101272A1 EA 200101272 A1 EA200101272 A1 EA 200101272A1 EA 200101272 A EA200101272 A EA 200101272A EA 200101272 A EA200101272 A EA 200101272A EA 200101272 A1 EA200101272 A1 EA 200101272A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
antagonists
receptors
integral
integrin receptors
Prior art date
Application number
EA200101272A
Other languages
English (en)
Inventor
Пол Дж. Коулман
Марк Е. Даггэн
Василь Халщенко
Джордж Д. Хартман
Джон Х. Хатчинсон
Роберт С. Мейсснер
Майкл А. Пэйтан
Джеймс Дж. Перкинс
Дзиабинг Ванг
Майкл Дж. Бреслин
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200101272A1 publication Critical patent/EA200101272A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Данное изобретение относится к новым производным нонановой кислоты, их синтезу и применению в качестве антагонистов альфа V интегриновых рецепторов. Точнее, соединения данного изобретения являются антагонистами интегриновых рецепторов альфа V бэта3 и альфа V бэта5 и полезны для ингибирования резорбции кости, лечения и профилактики остеопороза и ингибирования васкулярного рестеноза, диабетической ретинопатии, дегенерации желтого пятна, развития кровеносных сосудов, атеросклероза, воспаления, воспалительного артрита, вирусного заболевания, рака и метастатического роста опухоли.Отчет о международном поиске был опубликован 2000.09.22.
EA200101272A 1999-06-02 2000-05-30 Антагонисты альфа-v интегриновых рецепторов EA200101272A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13710199P 1999-06-02 1999-06-02
US17921600P 2000-01-31 2000-01-31
PCT/US2000/014901 WO2000072801A2 (en) 1999-06-02 2000-05-30 Alpha v integrin receptor antagonists

Publications (1)

Publication Number Publication Date
EA200101272A1 true EA200101272A1 (ru) 2002-06-27

Family

ID=26834930

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101272A EA200101272A1 (ru) 1999-06-02 2000-05-30 Антагонисты альфа-v интегриновых рецепторов

Country Status (28)

Country Link
US (1) US6410526B1 (ru)
EP (1) EP1187592B1 (ru)
JP (3) JP3808707B2 (ru)
KR (1) KR20020021380A (ru)
CN (1) CN1589145A (ru)
AT (1) ATE368462T1 (ru)
AU (1) AU749351B2 (ru)
BG (1) BG106232A (ru)
BR (1) BR0011108A (ru)
CA (1) CA2373937A1 (ru)
CY (1) CY1107746T1 (ru)
CZ (1) CZ20014308A3 (ru)
DE (1) DE60035779T2 (ru)
DK (1) DK1187592T3 (ru)
DZ (1) DZ3263A1 (ru)
EA (1) EA200101272A1 (ru)
EE (1) EE200100642A (ru)
ES (1) ES2288861T3 (ru)
HR (1) HRP20010895A2 (ru)
HU (1) HUP0302468A2 (ru)
IL (1) IL146378A0 (ru)
IS (1) IS6157A (ru)
NO (1) NO323906B1 (ru)
PL (1) PL353364A1 (ru)
PT (1) PT1187592E (ru)
SK (1) SK17442001A3 (ru)
TR (1) TR200103431T2 (ru)
WO (1) WO2000072801A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU780988B2 (en) 2000-01-24 2005-04-28 Merck & Co., Inc. Alpha V integrin receptor antagonists
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
EP1315501B1 (en) * 2000-07-26 2007-02-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001290772A1 (en) * 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
US20050101593A1 (en) * 2000-10-04 2005-05-12 Meissner Robert S. Phosphoric acid salt of an integrin receptor antagonist
EP1349548A4 (en) * 2001-01-03 2004-06-02 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1487489A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc METHODS FOR PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST ASSOCIATED WITH HMG-COA REDUCTASE INHIBITOR OR BISPHOSPHONATE
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058760A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
EP1603906A2 (en) * 2003-03-07 2005-12-14 Merck Sharp & Dohme Ltd. Process for synthesising useful intermediates for the preparation of alpha v beta 3 receptor antagonists
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EP2217238B1 (en) 2007-11-08 2014-03-12 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CA2899321C (en) * 2013-02-07 2021-03-09 Ben C. Askew Fluorinated .alpha..nu.integrin antagonists
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
PT3050878T (pt) 2013-09-24 2021-12-02 Fujifilm Corp Novo composto contendo azoto ou seu sal, ou seu complexo de metal
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
CA2976634C (en) * 2015-02-19 2023-10-17 Scifluor Life Sciences, Inc Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
JP2019524702A (ja) * 2016-07-05 2019-09-05 ザ ロックフェラー ユニバーシティー テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
US11014922B2 (en) * 2016-11-08 2021-05-25 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
EA201991121A1 (ru) * 2016-11-08 2019-11-29 АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
CA3054604A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
AU2019327475A1 (en) 2018-08-29 2021-03-11 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843798A (en) 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
US5025025A (en) 1989-06-28 1991-06-18 Ciba-Geigy Corporation (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
HUT68769A (en) 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
US5352667A (en) 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0760658B1 (en) 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
EP0880511A4 (en) 1996-01-16 1999-06-16 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
DE59706273D1 (de) 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
ATE227268T1 (de) 1996-04-10 2002-11-15 Merck & Co Inc Alpha v beta 3 antagonisten
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
CA2263999A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
EP0946164A4 (en) 1996-10-30 2000-08-23 Merck & Co Inc INTEGRIN ANTAGONISTS
ATE236626T1 (de) * 1996-10-30 2003-04-15 Merck & Co Inc Integrin antagonist
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
WO1999030713A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
PL341095A1 (en) 1997-12-17 2001-03-26 Merck & Co Inc Compounds acting as antagonists of integrin receptor
DE69829996T2 (de) * 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten

Also Published As

Publication number Publication date
CA2373937A1 (en) 2000-12-07
DE60035779T2 (de) 2008-04-30
US6410526B1 (en) 2002-06-25
BG106232A (en) 2002-06-28
EP1187592B1 (en) 2007-08-01
JP2004500326A (ja) 2004-01-08
IL146378A0 (en) 2002-07-25
AU749351B2 (en) 2002-06-27
JP2006206604A (ja) 2006-08-10
JP2006232844A (ja) 2006-09-07
CZ20014308A3 (cs) 2002-03-13
PL353364A1 (en) 2003-11-17
TR200103431T2 (tr) 2002-06-21
EP1187592A2 (en) 2002-03-20
DK1187592T3 (da) 2007-11-05
DE60035779D1 (de) 2007-09-13
DZ3263A1 (fr) 2000-12-07
EP1187592A4 (en) 2002-11-06
NO20015858L (no) 2002-02-04
NO323906B1 (no) 2007-07-16
ES2288861T3 (es) 2008-02-01
EE200100642A (et) 2003-02-17
WO2000072801A2 (en) 2000-12-07
ATE368462T1 (de) 2007-08-15
NO20015858D0 (no) 2001-11-30
CN1589145A (zh) 2005-03-02
PT1187592E (pt) 2007-10-19
CY1107746T1 (el) 2013-04-18
IS6157A (is) 2001-11-13
KR20020021380A (ko) 2002-03-20
HUP0302468A2 (hu) 2003-11-28
JP3808707B2 (ja) 2006-08-16
AU5724600A (en) 2000-12-18
WO2000072801A3 (en) 2007-10-11
HRP20010895A2 (en) 2003-08-31
BR0011108A (pt) 2002-03-19
SK17442001A3 (sk) 2002-03-05

Similar Documents

Publication Publication Date Title
EA200101272A1 (ru) Антагонисты альфа-v интегриновых рецепторов
DE69829996D1 (de) Integrin-rezeptor-antagonisten
ATE298338T1 (de) Integrin-rezeptor-antagonisten
ATE236626T1 (de) Integrin antagonist
ATE299023T1 (de) Integrinrezeptor antagonisten
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
ATE353219T1 (de) Alpha v integrin-rezeptor-antagonisten
WO2002090325A3 (en) Benzazepinone alpha v integrin receptor antagonists
ATE320258T1 (de) Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist
ECSP003775A (es) Antagonistas del receptor integrina alfa v
YU38300A (sh) Antagonisti integrinskog receptora
YU38200A (sh) Antagonisti integrinskog receptora